Related Experiment Video

Updated: Jul 6, 2026

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

Resveratrol directly targets COX-2 to inhibit carcinogenesis

Tatyana A Zykova1, Feng Zhu, Xiuhong Zhai

  • 1Hormel Institute, University of Minnesota, Austin, Minnesota 55912, USA.

Molecular Carcinogenesis
|April 3, 2008
PubMed

Insights

Resveratrol (RSVL) and its analogue RSVL-2 directly bind to cyclooxygenase-2 (COX-2), inhibiting cancer cell growth. This direct interaction with COX-2 is crucial for the anticancer effects observed in colon adenocarcinoma cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targeted cancer therapies aim to improve efficacy and reduce side effects by targeting specific proteins or genes.
  • Cyclooxygenase-2 (COX-2) is a key oncoprotein highly expressed in various cancers, making it a significant therapeutic target.
  • Resveratrol (RSVL) is a natural compound known to exhibit nonselective COX-2 inhibition.

Purpose of the Study:

  • To investigate the direct binding interaction between resveratrol (RSVL) and its analogues (RSVL-2, RSVL-3) with cyclooxygenase-2 (COX-2).
  • To determine if this direct binding is essential for the observed anticancer effects of RSVL and its analogues on colon cancer cells.
  • To compare the efficacy of RSVL and its analogues in inhibiting COX-2 activity and cancer cell growth.

Main Methods:

  • In vitro and ex vivo assays to assess the binding affinity of RSVL and its analogues to COX-2.
  • Measurement of COX-2-mediated prostaglandin E2 (PGE(2)) production.
  • Soft agar colony formation assays using HT-29 human colon adenocarcinoma cells (COX-2 positive) and COX-2 deficient cells to evaluate anchorage-independent growth suppression.

Main Results:

  • Resveratrol (RSVL) and RSVL-2 directly bind to COX-2, with RSVL-2 showing stronger binding than RSVL. RSVL-3 did not bind to COX-2.
  • RSVL and RSVL-2 inhibited COX-2-mediated PGE(2) production, while RSVL-3 did not.
  • RSVL and RSVL-2 suppressed anchorage-independent growth of HT-29 colon cancer cells, with significant growth inhibition (60% for RSVL, 80% for RSVL-2) observed in COX-2 positive cells.
  • Cancer cells deficient in COX-2 were unresponsive to RSVL and RSVL-2, indicating COX-2 dependency.

Conclusions:

  • The direct binding of resveratrol (RSVL) and RSVL-2 to COX-2 is a critical mechanism for their anticancer activity.
  • Targeting COX-2 with compounds like RSVL and RSVL-2 shows promise as a targeted therapy for cancers expressing this oncoprotein.
  • These findings highlight the potential of resveratrol and its analogues as direct COX-2 inhibitors for colon cancer treatment.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...